NCT06252649: An ongoing trial by Amgen
This trial is ongoing. It must report results 2 years, 7 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06252649 |
|---|---|
| Title | Phase 3 Multicenter, Randomized, Open-label, Active-controlled Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb for Treatment-naïve Subjects With Metastatic Colorectal Cancer With KRAS p.G12C Mutation (CodeBreaK 301) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | July 17, 2024 |
| Completion date | Jan. 31, 2028 |
| Required reporting date | Jan. 30, 2029, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | June 9, 2026 |
| Days late | None |